Related references
Note: Only part of the references are listed.Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study
Irene Eriksson et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study
Giulia Mallucci et al.
JOURNAL OF NEUROLOGY (2018)
Multiple Sclerosis
Daniel S. Reich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Real-life persistence and tolerability with dimethyl fumarate
Tobias Sejbaek et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)
Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers
Brandi Vollmer et al.
NEUROLOGY-CLINICAL PRACTICE (2018)
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience
Emanuele D'Amico et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2018)
Persistence to oral disease-modifying therapies in multiple sclerosis patients
Simona Lattanzi et al.
JOURNAL OF NEUROLOGY (2017)
Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach
Tjalf Ziemssen et al.
BMC NEUROLOGY (2016)
Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs
Emanuele D'Amico et al.
DRUG SAFETY (2016)
Long-term safety and efficacy of teriflunomide Nine-year follow-up of the randomized TEMSO study
Paul O'Connor et al.
NEUROLOGY (2016)
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives
Emanuele D'Amico et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal
Emanuele D'Amico et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal
Emanuele D'Amico et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study
J. Theodore Phillips et al.
NEUROLOGY AND THERAPY (2015)
Fostering adherence to injectable disease-modifying therapies in multiple sclerosis
Alessandra Lugaresi et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2014)
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
Christian Confavreux et al.
LANCET NEUROLOGY (2014)
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Robert J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response
Hans-Georg Eichler et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Share Paper
